Neuroendocrine responses in chronic schizophrenia. Evidence for serotonergic dysfunction.
Neuroendocrine and mood responses to a 60 mg oral dose of the serotonin-releasing agent, fenfluramine, were assessed in ten neuroleptic-free, chronic schizophrenic patients and in age- and sex-matched normal control subjects. The prolactin (PRL) response to fenfluramine was significantly blunted in the schizophrenic subjects. Growth hormone and cortisol levels were not differentially affected by the challenge. There was no significant effect of fenfluramine on mood in either group. The blunted PRL response in the schizophrenic group suggests serotonergic dysfunction; possible mechanisms of this finding and implications for treatment are considered.
Lerer
B
B
Jerusalem Mental Health Center-Ezrath Nashim Hospital, Israel.
Ran
A
A
Blacker
M
M
Silver
H
H
Weller
M P
MP
Drummer
D
D
Ebstein
B
B
Calev
A
A
D000328:Adult; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008875:Middle Aged; D009490:Neurosecretory Systems / Q000503:physiopathology*; D011388:Prolactin / Q000097:blood; D012559:Schizophrenia / Q000503:physiopathology*; D012701:Serotonin / Q000502:physiology*
D012701:Serotonin; D011388:Prolactin; D013006:Growth Hormone; D006854:Hydrocortisone